RNA-interference Market Analysis and Forecast to 2031: By Technology (Nanoparticle Drugs, Pulmonary Drugs, Others), Application (Infectious Disease, Cardiology, Others), and Region

RNA interference (RNAi) is a process in which RNA molecules are used to inhibit gene expression or silence genes. RNAi occurs naturally in plants and animals and has been harnessed as a tool for biotechnology and medicine. RNAi is triggered by the presence of double-stranded RNA (dsRNA). When dsRNA is introduced into a cell, it is processed by an enzyme called Dicer into small interfering RNA (siRNA). SiRNA consists of two strands of RNA that are complementary to each other and bind to each other to form a double-stranded molecule. SiRNA then binds to a protein called RNA-induced silencing complex (RISC), which cleaves the complementary RNA strand. This process leads to the degradation of mRNA and the inhibition of gene expression.

Key Trends

One trend is the increasing use of RNAi in vivo, in animal models of disease, and in agricultural settings. This is driven in part by the development of more effective delivery methods, such as lipid nanoparticles and viruses.

Another trend is the increasing use of RNAi for target validation, as it provides a quick and efficient way to assess the function of a gene of interest.

Finally, the increasing use of next-generation sequencing (NGS) to generate siRNA libraries is providing a powerful tool for functional genomics studies.

Key Drivers

The key drivers of the RNA-interference market are the increasing demand for RNA-based therapeutics, the rising prevalence of chronic diseases, and the growing investment in RNA-based research.

The demand for RNA-based therapeutics is increasing due to the growing understanding of the role of RNA in disease pathogenesis.

The prevalence of chronic diseases is rising due to the aging population and the growing prevalence of lifestyle diseases. Chronic diseases are often associated with aberrant gene expression, making RNA-based therapeutics an attractive treatment option.

The investment in RNA-based research is growing due to the increasing understanding of the role of RNA in disease pathogenesis and the potential of RNA-based therapeutics.

Restraints & Challenges

There are several key restraints and challenges in the RNA-interference market.

First, RNA-interference is a relatively new technology, and there is still much to learn about its potential applications and limitations.

Second, RNA-interference is often considered to be a “black box” technology, meaning that its mechanisms are not fully understood. This lack of understanding can make it difficult to design effective RNA-interference treatments and to predict their side effects.

Finally, RNA-interference is a complex and expensive technology, and its commercial success will depend on the development of more efficient and cost-effective methods for delivering RNA-interference treatments to patients.

Market Segments

The RNA-interference market is segmented by technology, application, and region. By technology, the market is classified into nanoparticle drugs, pulmonary drugs, and others. Based on the application, it is bifurcated into infectious disease, cardiology, and others. Region-wise, the market is segmented into North America, Europe, Asia Pacific, and the rest of the World.

Key Players

The RNA-interference market includes players such as Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc, Silence Therapeutics Plc, and others.

Why GIS?

Table of Contents

Chapter 1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Methodologies
1.4. Market Estimation Techniques

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market

Chapter 3. RNA-interference Market Outlook
3.1. RNA-interference Market Segmentation
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.3. Porter’s Five Forces Analysis
3.3.1. Threat of New Entrants
3.3.2. Threat of Substitutes
3.3.3. Bargaining Power of Buyers
3.3.4. Bargaining Power of Supplier
3.3.5. Competitive Rivalry
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.5.1. Raw Material Suppliers
3.5.2. Manufacturers
3.5.3. Wholesalers and/or Retailers
3.6. Impact of the Russia and Ukraine War on the Global RNA-interference Market

Chapter 4. Economic Impact of COVID-19
4.1. Overall Impact of COVID-19
4.2. Impact of COVID On the Global RNA-interference Market
4.3. Economic Impact Analysis

Chapter 5. RNA-interference Market by Application
5.1. Market Overview
5.2. Infectious Disease
5.2.1. Market Size and Forecast, 2021-2031 ($Million)
5.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.3. Cardiology
5.3.1. Market Size and Forecast, 2021-2031 ($Million)
5.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.4. Others
5.4.1. Market Size and Forecast, 2021-2031 ($Million)
5.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 6. RNA-interference Market by Technology
6.1. Market Overview
6.2. Nanoparticle Drug
6.2.1. Market Size and Forecast, 2021-2031 ($Million)
6.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.3. Pulmonary Drug
6.3.1. Market Size and Forecast, 2021-2031 ($Million)
6.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.4. Others
6.4.1. Market Size and Forecast, 2021-2031 ($Million)
6.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 7. RNA-interference Market, by Region
7.1. Overview
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. North America RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.2.3. North America RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.2.4. North America RNA-interference Market Size and Forecast by Country, 2021-2031, ($Million)
7.2.5. The U.S.
7.2.5.1. The U.S. RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.2.5.2. The U.S. RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.2.6. Canada
7.2.6.1. Canada RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.2.6.2. Canada RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.2.7. Mexico
7.2.7.1. Mexico RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.2.7.2. Mexico RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)

7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Europe RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.3. Europe RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.4. Europe RNA-interference Market Size and Forecast by Country, 2021-2031, ($Million)
7.3.5. Germany
7.3.5.1. Germany RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.5.2. Germany RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.6. France
7.3.6.1. France RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.6.2. France RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.7. U.K.
7.3.7.1. U.K. RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.7.2. U.K. RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.8. Spain
7.3.8.1. Spain RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.8.2. Spain RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.9. Italy
7.3.9.1. Italy RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.9.2. Italy RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.3.10.2. Rest of Europe RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)

7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Asia-Pacific RNA-interference Market Size and Forecast by Country, 2021-2031, ($Million)
7.4.3. Asia-Pacific RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.4. Asia-Pacific RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.4.5. China
7.4.5.1. China RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.5.2. China RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.4.6. India
7.4.6.1. India RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.6.2. India RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.4.7. Japan
7.4.7.1. Japan RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.7.2. Japan RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.4.8. South Korea
7.4.8.1. South Korea RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.8.2. South Korea RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.4.9. Rest of APAC
7.4.9.1. Rest of APAC RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.4.9.2. Rest of APAC RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)

7.5. Rest of the World
7.5.1. Key Market Trends and Opportunities
7.5.2. Rest of the World RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.5.3. Rest of the World RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.5.4. Rest of the World RNA-interference Market Size and Forecast by Country, 2021-2031, ($Million)
7.5.5. Latin America
7.5.5.1. Latin America RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.5.5.2. Latin America RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.5.6. Middle East
7.5.6.1. Middle East RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.5.6.2. Middle East RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)
7.5.7. Africa
7.5.7.1. Africa RNA-interference Market Size and Forecast by Application, 2021-2031, ($Million)
7.5.7.2. Africa RNA-interference Market Size and Forecast by Technology, 2021-2031, ($Million)

Chapter 8. Competitive Landscape
8.1. Market Overview
8.2. Market Share Analysis/Key Player Positioning
8.3. Developmental Strategy Benchmarking
8.3.1. New Product Development
8.3.2. Product Launches
8.3.3. Business Expansions
8.3.4. Partnerships, Joint Ventures, and Collaborations
8.3.5. Mergers and Acquisitions

Chapter 9. Company Profiles
9.1. Alnylam Pharmaceuticals Inc.
9.1.1. Company Snapshot
9.1.2. Financial Performance
9.1.3. Product Offerings
9.1.4. Key Strategic Initiatives
9.1.5. SWOT Analysis
9.2. Arrowhead Pharmaceuticals Inc.
9.2.1. Company Snapshot
9.2.2. Financial Performance
9.2.3. Product Offerings
9.2.4. Key Strategic Initiatives
9.2.5. SWOT Analysis
9.3. CureVac AG
9.3.1. Company Snapshot
9.3.2. Financial Performance
9.3.3. Product Offerings
9.3.4. Key Strategic Initiatives
9.3.5. SWOT Analysis
9.4. Dicerna Pharmaceuticals Inc.
9.4.1. Company Snapshot
9.4.2. Financial Performance
9.4.3. Product Offerings
9.4.4. Key Strategic Initiatives
9.4.5. SWOT Analysis
9.5. Gradalis Inc.
9.5.1. Company Snapshot
9.5.2. Financial Performance
9.5.3. Product Offerings
9.5.4. Key Strategic Initiatives
9.5.5. SWOT Analysis
9.6. Ionis Pharmaceuticals Inc
9.6.1. Company Snapshot
9.6.2. Financial Performance
9.6.3. Product Offerings
9.6.4. Key Strategic Initiatives
9.6.5. SWOT Analysis
9.7. Merck & Co. Inc.
9.7.1. Company Snapshot
9.7.2. Financial Performance
9.7.3. Product Offerings
9.7.4. Key Strategic Initiatives
9.7.5. SWOT Analysis
9.8. Moderna Inc.
9.8.1. Company Snapshot
9.8.2. Financial Performance
9.8.3. Product Offerings
9.8.4. Key Strategic Initiatives
9.8.5. SWOT Analysis
9.9. Quark Pharmaceuticals Inc
9.9.1. Company Snapshot
9.9.2. Financial Performance
9.9.3. Product Offerings
9.9.4. Key Strategic Initiatives
9.9.5. SWOT Analysis
9.10. Silence Therapeutics Plc
9.10.1. Company Snapshot
9.10.2. Financial Performance
9.10.3. Product Offerings
9.10.4. Key Strategic Initiatives
9.10.5. SWOT Analysis

*The list of companies is subject to change during the final compilation of the report

 

 

Market Segmentation

By Technology

  • Nanoparticle Drug
  • Pulmonary Drug
  • Others

By Application

  • Infectious Disease
  • Cardiology
  • Others

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Rest of APAC
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

The global micro surgical robot market was valued…
The global brain cancer diagnostics market was valued…
The Wound Dressings market was valued at USD…